Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.27 CHF | -0.03% |
|
-1.53% | +19.25% |
06-14 | Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA | CI |
06-07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Sales 2024 * | 10.29B 9.24B 815B | Sales 2025 * | 10.96B 9.83B 868B | Capitalization | 15.51B 13.92B 1,229B |
---|---|---|---|---|---|
Net income 2024 * | 710M 637M 56.26B | Net income 2025 * | 974M 874M 77.17B | EV / Sales 2024 * | 1.81 x |
Net Debt 2024 * | 3.12B 2.8B 247B | Net Debt 2025 * | 2.73B 2.45B 216B | EV / Sales 2025 * | 1.66 x |
P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
15.9
x | Employees | 22,633 |
Yield 2024 * |
1.76% | Yield 2025 * |
2.27% | Free-Float | 91.29% |
Latest transcript on Sandoz Group AG
1 day | -0.48% | ||
1 week | -1.53% | ||
Current month | +0.66% | ||
1 month | -0.74% | ||
3 months | +20.41% | ||
6 months | +20.10% | ||
Current year | +19.25% |
![Extreme 31.71](/images/extremecours_fleche.png)
![Extreme 30.76](/images/extremecours_fleche.png)
![Extreme 25.33](/images/extremecours_fleche.png)
![Extreme 22.7](/images/extremecours_fleche.png)
![Extreme 22.7](/images/extremecours_fleche.png)
![Extreme 22.7](/images/extremecours_fleche.png)
![Extreme 22.7](/images/extremecours_fleche.png)
Date | Price | Change | Volume |
---|---|---|---|
26/06/24 | 32.27 | -0.03% | 922 199 |
25/06/24 | 32.28 | +0.47% | 888,845 |
24/06/24 | 32.13 | -1.98% | 1,165,037 |
21/06/24 | 32.78 | -0.49% | 2,122,455 |
20/06/24 | 32.94 | +0.52% | 950,207 |
Delayed Quote Swiss Exchange, June 26, 2024 at 04:30 pm
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.25% | 15.51B | |
+20.78% | 43.29B | |
+27.64% | 22.38B | |
+18.68% | 14.52B | |
+54.64% | 12.93B | |
-0.05% | 6.79B | |
-11.39% | 6.56B | |
+18.33% | 5.87B | |
-8.87% | 5.73B | |
+6.11% | 4.68B |
- Stock Market
- Equities
- SDZ Stock